Jason Freeman, MD, MBA

Jason Freeman, MD, MBA, and James Stankiewicz, MD, discuss the poster “Real-World Experience With Ofatumumab” presented at ACTRIMS 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Quality of Life and Treatment Satisfaction With Disease-Modifying Therapies in Multiple Sclerosis” presented at ACTRIMS 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Shankar Sadasivan, PhD, discuss the poster “Immunoglobulins in Primary Progressive and Relapsing-Remitting Multiple Sclerosis” presented at ACTRIMS 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Five-Year Safety of Ofatumumab in People Living with Relapsing Multiple Sclerosis” presented at AAN 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and D'Andra Parker, PhD, discuss highlights from ACTRIMS 2023, with a focus on diversity in clinical studies. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Arsalan Syed, PhD, discuss highlights from the session “Multiple Sclerosis Disease Modifying Treatments” presented at AAN 2023. Sponsored By Novartis